A medical app for treatment of mixed- and urgency urinary incontinence within healthcare
| Reference number | |
| Coordinator | eContinence AB |
| Funding from Vinnova | SEK 200 000 |
| Project duration | October 2025 - October 2026 |
| Status | Ongoing |
| Venture | Medtech4Health: Competence Enhancement in SME |
| Call | Medtech4Health: Competence Enhancement in Small Businesses 2025 |
Purpose and goal
eContinence AB works to utilize apps, which were developed and evaluated within the research project Tät.nu at Umeå University. The Tät®II app includes bladder training, pelvic floor exercises and support. App treatment resulted in reduced leakage, fewer urges, reduced need for incontinence aids and increased quality of life compared to an information app. Objective: To launch the medical CE-marked app Tät®II for the treatment of urgency and mixed incontinence via healthcare services
Expected effects and result
The Tät® app for the treatment of stress urinary leakage is a CE-marked medical app, which has been evaluated in research. So far, it has been used by more than 400,000 women. The Tät®II app is another CE-marked medical app, evaluated in research. It is aimed at women with urgency or mixed urinary leakage. We want to offer the app through the healthcare. In this way, access to care aimed at reducing symptoms and increasing quality of life is increased. Cost savings for healthcare.
Planned approach and implementation
Work in collaboration with a technical consultant; Update, development and adaptation including building the backend to be able to launch the app via healthcare services. The Tät® II app is CE marked as a medical device class I according to Regulation (EU) 2017/745 MDR. In parallel with the technical work, workshops are carried out with a regulatory consultant. We review the technical documentation and the changes in our QMS that are needed before the release of the app in a new design.